In the present study, we examined the underlying mechanism, which causes the constitutive tyrosine phosphorylation of signal transducer and activator of transcription 5 (STAT5) in acute myeloid leukemia (AML) blasts. Constitutive STAT5 phosphorylation was observed in 18 of 26 (69%) patients with AML. The constitutive STAT5 phosphorylation was caused by different mechanisms. In the majority of the investigated cases (71% (12 of 17)) constitutive STAT5 phosphorylation was associated with autophosphorylation of the type III receptor tyrosine kinase These data indicate that in the majority of AML cases the constitutive STAT5 phosphorylation is caused by Flt3 phosphorylation mostly due to mutations in the receptors and associated with a low degree of spontaneous apoptosis. Leukemia (2001Leukemia ( ) 15, 1923Leukemia ( -1931 
Introduction
Acute myeloid leukemia (AML) is characterized by an accumulation of immature blast cells in the bone marrow, finally resulting in disturbed production of normal hematopoietic cells. 1 AML is often associated with chromosomal translocations and somatic mutations, affecting gene expression in ways that lead to defects in normal programs of cell proliferation, differentiation and survival. [2] [3] [4] [5] Targets of those genetic alterations are most frequently intermediates of intracellular signaling pathways, resulting in aberrant and constitutive signal transduction in AML. 2, 4, 6 Intracellular signal transduction pathways are normally tightly regulated through activation of growth factors and cytokines. One of the signal transduction pathways which is activated by cytokines such as IL-3, IL-5 and GM-CSF is the Jak2/STAT5 (Janus kinase/signal transducer and activator of transcription) pathway. 7, 8 Jak2 is a cytoplasmic tyrosine kinase that associates with cytokine receptors and is responsible for a range of phosphorylation events, including the cytokine receptors, upon stimulation. 9 STAT5 is a latent cytoplasmic transcription factor that becomes tyrosine phosphorylated and activated after recruitment to an activated receptor complex. 10 STAT5 exists as two homologous proteins referred to as STAT5A and STAT5B, which are encoded by two different genes. 7 Tyrosine phosphorylation of STAT5 induces dimerization, translocation to the nucleus and binding to specific promoter sequences to induce transcription of specific target genes. 10 A small number of genes have been shown to be regulated by STAT5, including ␤-casein, cyclinD1, CIS, OSM and Bcl-xl. [11] [12] [13] [14] [15] Bcl-xl has been described to be involved in the prevention of apoptosis by modulating the mitochondrial membrane potential resulting in the prevention of cytochrome C release. 16 Recently, it has been described that STATs (STAT 1, 3 and 5) are constitutively tyrosine phosphorylated and activated in AML blasts, which might contribute to the leukemic phenotype. 17, 18 Constitutive STAT activation might be due either to the constitutive activation of cytokine receptors activated by autocrine growth factors or due to mutations in specific upstream tyrosine kinases resulting in constitutive activity of these kinases. A recent report demonstrated that constitutive STAT3 activation in AML is caused by the autocrine secretion of IL-6. 19 In contrast, for chronic myelogenous leukemia it has recently been shown that STAT5 plays a role in cellular transformation by the Bcr/Abl chimeric oncogene. 20 In Bcr/Abl transformed cells, STAT5 is constitutively activated and contributes to the growth and viability of these cells. Expression of dominant negative STAT5 reduced the growth rate of Bcr/Abl transformed Ba/F3 cells by inhibiting viability and increasing sensitivity to chemotherapeutic drugs. In addition, expression of a TEL-Jak2 fusion protein in Ba/F3 cells resulted in conversion of these cells to factor independence. 21 Fusion of TEL to the kinase or the kinase plus pseudokinase domain of Jak2 resulted in constitutive activation of the fusion protein and in the constitutive tyrosine phosphorylation of STAT1, 3 and 5.
Recently, in AML blasts mutations in the fms-like tyrosine (Flt3) receptor kinase have been described. The Flt3 receptor belongs to the group of class III receptor tyrosine kinases which also include c-KIT, c-FMS and platelet-derived growth factor (PDGF). [22] [23] [24] Flt3 and its ligand FL play an important role in the survival and self-renewal of early multipotent hematopoietic progenitors. 25, 26 In addition, Flt3 ligand caused a proliferative response in a considerably high percentage of AML cases. 27 Signals generated by ligand-induced dimerization of this receptor involve tyrosine phosphorylation of certain regions of the receptor and activation of cellular tyrosine kinases. It has been proposed that Flt3 has the ability to phosphorylate several kinases including Shc, the p85 subunit of PI3 kinase and mitogen-activated protein (MAP) kinase. 28 Zhang et al 29 demonstrated that stimulation of Baf3 or Cos-7 cells, which stably express full-length human Flt3 receptor, resulted in activation of STAT5a.
It was shown that internal tandem duplications (ITDs) in the part of the Flt3 gene coding for the juxtamembrane (JM) through first tyrosine kinase (TK-1) domains of the protein occur in 20% of AML cases. 30 It appeared that in patients with a mutation in Flt3 the complete remission rates were reduced and relapse rates were increased, indicating that Flt3 mutations are associated with a poor prognosis. 31 34 demonstrated that Flt3-ITD mutations induce factor-independent growth and leukemogenesis of 32D cells that are mediated by the Ras and STAT5 pathways. These findings indicate that leukemic cells have the capacity to modulate the expression and activity of STATs in several ways, either by autocrine production of growth factors or by receptor or oncogenic activation.
In the present study, we examined the underlying mechanism that results in constitutive STAT5 activation in AML blasts.
Here, we report that constitutive STAT5 phosphorylation in AML is caused by different mechanisms. In the majority of the cases constitutive STAT5 phosphorylation was associated with spontaneous phosphorylation of the Flt3 receptor, in part as a result of Flt3 mutations. Furthermore, the AML cases with high STAT5 and Flt3 phosphorylation demonstrated, in general, a lower percentage of apoptotic cells, compared to AML blasts with no STAT5 phosphorylation. These data suggest that constitutive active Flt3 contributes to the prevention of apoptosis of AML blast through activation of STAT5.
Materials and methods

Patient population and isolation of AML cells
Peripheral blood cells or bone marrow cells from 26 adult untreated patients with AML were studied after informed consent. The AML cases were defined according to the classification of the French-American-British (FAB) committee as M0-M6. 35 AML blasts were isolated by density-gradient centrifugation. The cells were cryopreserved in aliquots of 20-30 × 10 6 cells in RPMI 1640 supplemented with 10% dimethylsulfoxide (DMSO; Sigma, St Louis, MO, USA) and 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), employing a method of controlled freezing and storage in liquid nitrogen. After thawing, T lymphocytes were depleted by 2-aminoethylisothioronium bromide (AET)-treated sheep red blood cell (SRBC) rosetting. The cell population consisted of more than 98% AML blasts as determined by May-Grü nwald-Giemsa staining. Fluorescence-activated cell sorting (FACS) analysis demonstrated Ͻ1% CD3 (Becton Dickson, Sunnyvale, CA, USA) positive cells. AML blasts were cultured at 37°C at a density of 1 × 10 6 /ml in RPMI 1640 media (Flow, Rockville, MD, USA) supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 6 ng/ml of colistine and 10% FBS.
Combined annexin V/PI staining procedure
Viability was assessed by using an annexin V staining kit (IQ Products, Groningen, The Netherlands) according to the manufacturer's recommendations. Briefly, after 24 h of culture in RPMI 1640 medium supplemented with 10% FBS, with or without AG1296 (20 M) (Calbiochem, La Jolla, CA, USA), cells were harvested, resuspended in 100 l calcium buffer containing 5 l of annexin V and incubated for 20 min at 4°C in the dark. Cells were washed with 5 ml calcium buffer and subsequently incubated in 300 l calcium buffer containing 2.5 l of propidium iodide (PI) for 10 min in the dark. Subsequently, binding of fluorescein-conjugated annexin V and PI was measured by fluorescence-activated cell sorting (Becton Dickinson).
Western blotting
The amount of STAT5 A/B, ERK, Bcl-xl, actin and the degree of phosphorylated STAT5 and ERK were determined by Western blotting. AML blasts were cultured for 24 h in RPMI 1640 supplemented with 10% FBS, with or without AG1296 (20 M) (Calbiochem), with or without AG490 (100 m) (Calbiochem, La Jolla, CA), with or without FL (100 ng/ml) (a friendly gift from Immunex Corporation, Seattle, WA) or with or without anti-GM-CSF antibody (1 g/ml) (R&D Systems, Abingdon, UK) at a density of 1 × 10 6 cells/ml. AML blasts were cultured for 24 h in RPMI 1640 supplemented with 10% FBS and subsequently stimulated for 15 min with conditioned AML medium (prepared by incubating AML cells at a density of 3 × 10 6 cells/ml for 3 days) or FL (100 ng/ml). 3 × 10 6 cells were harvested and total cell extracts were prepared by resuspending the cells in 100 l 1× sample buffer (containing 2% SDS, 10% glycerol, 2% ␤-mercapthoethanol, 60 mM Tris-HCl pH 6.8 and bromophenol blue). Cell extracts were directly boiled for 5 min and proteins were fractionated by running on SDS PAGE gel. The proteins were electrophoretically transferred to PVDF membrane (Millipore, Bedford, MA, USA) and probed with polyclonal antibodies against STAT5 A/B (Upstate Biotechnology, Lake Placid, NY, USA), phosphorylated STAT5 or ERK (New England BioLabs, Beverly, MA, USA), ERK (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) or monoclonal antibody against Bcl-xl (Zymed, South San Francisco, CA, USA) or actin (Boehringer, Mannheim, Germany). Immunocomplexes were detected using enhanced chemiluminescence (ECL; Amersham, Uppsala, Sweden).
Immunoprecipitation
2 × 10 7 AML blasts were cultured for 24 h in RPMI 1640 medium supplemented with 10% FBS, with or without AG1296 (20 M), and subsequently stimulated for 5 min with or without FL (100 ng/ml). Cells were harvested, washed with ice-cold PBS containing 1 mM sodium orthovanadate and subsequently lysed in 500 l lysisbuffer (50 mM Hepes, pH 7.4, 10% glycerol, 150 mM NaCl, 1% Triton X-100, 1mM EDTA, 1mm EGTA, 25 mM NaF, proteinase inhibitors (Complete; Boehringer Mannheim), 1 M pepstatin, 1 mM sodium orthovanadate) for 10 min on ice. Cell lysates were clarified at 20 000 g for 20 min and then precleared with 30 l Protein A Sepharose beads (50% slurry) for 1 h at 4°C. After 5 min centrifugation at 380 r.p.m., the cell lysates were incubated with 5 l Flt3 antibody (C-20, Santa Cruz) rotating overnight at 4°C. Protein A sepharose beads (30 l) were added to each sample and incubated for another 4 h at 4°C. The immune complex was washed three times with lysis buffer. One-tenth of the precipitate was analyzed for the amount of precipitated Flt3 protein and 9/10ths of the precipitate were analyzed for the degree of tyrosine phosphorylated Flt3. The immune complexes were heated in sample buffer, separated by SDS PAGE, immunoblotted on PVDF membrane (Millipore) and incubated overnight with either anti-phosphotyrosine (4G10, Up-state Biotechnology) or anti-Flt3 antibody. Immunocomplexes were detected using ECL (Amersham).
Analysis of the internal tandem duplication of the Flt3 gene
High molecular weight DNA was extracted from AML cells as previously described. 36 Previous studies showed that the location of internal tandem duplication of the Flt3 gene was restricted to exons 11 and 12. Therefore, genomic PCR amplification was performed using the primers 11Forward : 5Ј-GCAATTTAGGTATGAAAGCCAGC-3Ј and 12Reverse: 5Ј-CTTTCAGCATTTTGACGGCAACC-3Ј. The PCR was performed using 200 ng of genomic DNA in a total volume of 50 l using 1 U of Taq polymerase (Gibco BRL) according to the manufacturer's recommendations.
The amplified PCR product was run on a 7.5% acryl/bisacrylamide gel (29:1) cut out from the gel and dissolved in 40 l H 2 O overnight at 4°C. Using 20 l of the in water dissolved PCR product the PCR reaction was performed again under the same conditions as described above. The amplified PCR product was purified with a PCR purification kit (Qiagen, Chatsworth, CA, USA) and directly sequenced using the 11FW primer.
Results
Constitutive STAT5 phosphorylation
Firstly, the phosphorylation status of STAT5 was assessed in fresh human AML blasts of 26 untreated patients with AML (FAB classifications: M1 (n = 7), M2 (n = 9), M4 (n = 7), M5 (n = 2), M6 (n = 1)). Therefore, AML blasts were cultured for 24 h in 10% FBS and STAT5 tyrosine phosphorylation was determined using a phospho-specific antibody. Fourteen of the 26 investigated AML cases (54%) demonstrated a relatively high degree of constitutive STAT5 phosphorylation, four cases demonstrated a low level of STAT5 phosphorylation, while eight cases demonstrated no phospho-STAT5 (representative data are shown in Figure 1 and summarized in Table 1 ). In addition, the expression level of STAT5 was studied for the different AML cases, demonstrating that the amount of STAT5 protein varied strongly between the different AML cases. Most of the AML cases with high constitutive STAT5 phosphorylation had, in general, higher STAT5 expression levels than those with low levels of phospho-STAT5, while the amount of total protein, detected by actin staining, was of equal proportion for each AML case. The degree of constitutive STAT5 phosphorylation did not correlate with the FAB classification of the AML cases.
Flt3 receptor is mutated and constitutively activated in the majority of the STAT5-positive AML cases
Somatic mutation of the Flt3 receptor tyrosine kinase, in which the juxtamembrane domain has an internal tandem duplication, has been found in 20% of AML cases. 30 The mutation results in constitutive tyrosine phosphorylation of the receptor. 32 Flt3 mutations have been described to result in activation of STAT5. 33, 34 In order to elucidate the underlying mechanism of constitutive STAT5 activation in AML, we investigated whether Flt3 might be constitutively activated in
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Figure 1
STAT5 expression and phosphorylation patterns of the investigated patients with AML. AML cells were cultured for 24 h in RPMI 1640 supplemented with 10% FBS. Total cell extracts were prepared and equal amounts of cell lysates were subjected to SDS-PAGE. Western blot analysis was performed using an antibody against phospho-STAT5. As a control, equal amounts of total cell lysates were Western blotted using antibodies against STAT5 A/B and actin. (Representative data from 15 cases are shown.) the AML cases with high STAT5 phosphorylation. Flt3 was immunoprecipitated from the AML cells after 24 h of culture in 10% FBS and the expression and autophosphorylation of the receptors were analyzed. As demonstrated in Figure 2a and summarized in Table 1 , the expression levels of Flt3 varied strongly among the different AML cases, while the amount of total protein was of equal proportions for each AML case (not shown). Constitutive phosphorylation of Flt3 was shown in 12 of 23 (52%) investigated cases. These correlated in 10 of 12 (83%) with high STAT5 tyrosine phosphorylation and in two of 12 (17%) with low STAT5 phosphorylation.
Next, we were interested whether the constitutive activation of Flt3 was due to tandem duplications in the juxtamembrane domain. Therefore, the part of the genomic DNA encoding the juxtamembrane region was amplified by PCR. Eleven out of 25 investigated AML cases displayed a PCR product that was slightly larger than that of the control cells (healthy human monocytes), of which 10 cases displayed a double band (heterozygous mutation) and only one the larger product (homozygous mutation) (summarized in Table 1 ). DNA sequencing of the products confirmed that the larger bands contained an insertion and the lower bands corresponded to the wild-type Flt3. Sequence analysis of the Flt3 mutant samples showed tandem duplications varying in length from eight to 12 amino acids (data not shown). Seventy-three percent of the cases with Flt3 mutations demonstrated autophosphorylation of the receptor. To examine whether Flt3 mutations resulted in maximal activation of the receptor, AML cases were stimulated with Flt3 ligand (FL) and the phos- (Figure 2b ). This in contrast to the AML with a homozygous mutation (No. 3), this AML was not responsive to FL. Next, we examined whether the spontaneous phosphorylation of Flt3 of the four AML cases (Nos 1, 11, 21 and 26) with no mutation might be caused by autocrine production of Flt3 ligand. Therefore, these four AML blasts were cultured for 3 days in 10% FBS and the cell-free supernatants were collected. Subsequently, an AML case with no spontaneous STAT5 phosphorylation, which is highly responsive to FL (No. 23), was stimulated for 10 min with the AML conditioned medium. As demonstrated in Figure 2c , the cell-free supernatants of the four AML cases had no effect on STAT5 phosphorylation.
The data described above indicate that in 71% of the cases STAT5 phosphorylation is associated with Flt3 phosphorylation.
However, three of the investigated AML cases (Nos 2, 7 and 8) demonstrated high constitutive STAT5 phosphorylation without autophosphorylation of or mutations in Flt3. Therefore, some other mechanism might be responsible for the constitutive STAT5 phosphorylation. We examined whether autocrine production of GM-CSF, which has been described as one of the more frequently expressed growth factors by AML, 37 might be the cause for the constitutive STAT5 phosphorylation. Therefore, these AML blasts were cultured for 24 h with a neutralizing antibody for GM-CSF to deplete the possibly secreted GM-CSF and the effect on STAT5 phosphorylation was examined. As demonstrated in Figure 2d , in two of the three AML cases anti-GM-CSF inhibited the constitutive STAT5 phosphorylation, indicating that the autocrine production of GM-CSF partly accounts for the constitutive STAT5 phosphorylation in these AML cases.
Specific receptor tyrosine kinaseIII inhibitor AG1296 inhibited Flt3 and STAT5 phosphorylation
In order to investigate the link between Flt3 and STAT5 in more detail, the effect of the specific receptor tyrosine kinaseIII inhibitor AG1296, 29 which has been described earlier as a potent inhibitor for Flt3, on the FL-induced STAT5 phosphorylation was examined. As demonstrated in Figure 3a , addition of FL resulted in a strong increase of STAT5 phosphorylation, which was strongly inhibited by AG1296. Similarly, stimulation with FL strongly enhanced phosphorylation of the ERK MAP kinase (another downstream target of Flt3), which was also inhibited by AG1296. In contrast, AG1296 had no effect on the GM-CSF-induced STAT5 tyrosine phosphorylation, while the specific JAK2 inhibitor AG490 38 strongly inhibited STAT5 phosphorylation, demonstrating that AG1296 is specific for receptor tyrosine kinases (Figure 3b ). In addition, stimulation with FL also strongly induced STAT5 phosphorylation of the monocytic leukemia cell line THP-1, which was completely inhibited by AG1296 (data not shown). THP-1 cells do not contain a Flt3 mutation, demonstrating that wild-type Flt3 is able to activate STAT5. Finally, the inhibitory effect of AG1296 on ligand-induced phosphorylation of the Flt3 receptor of an AML case without a mutation or constitut-ive Flt3 phosphorylation was confirmed. As demonstrated in Figure 3c , stimulation with FL strongly induced Flt3 phosphorylation, which was completely inhibited by AG1296.
Next, we tested whether AG1296 could inhibit the constitutive phosphorylation of STAT5. As depicted in Figure 4 , AG1296 inhibited the spontaneous phosphorylation of Flt3 and the constitutive phosphorylation of STAT5 of the investigated AML cases (n = 4). However, the spontaneous Flt3 phosphorylation of an AML case with a homozygous (No. 3) or a heterozygous (No. 6) mutation was not inhibited by AG1296, while STAT5 phosphorylation was inhibited.
It has been described that AG1296 can also inhibit the ckit receptor tyrosine kinase, which has been shown to be expressed by approximately 60% of the AML cases. 39, 40 To demonstrate the specificity of the inhibitive effect of AG1296, three AML cases (which were expressed on 80% or more of the cells c-kit receptor) were stimulated with stem cell factor (the ligand for c-kit) with or without addition of AG1296. Addition of SCF had no significant effect on STAT5 phosphorylation, while ERK phosphorylation was strongly enhanced (data not shown). The SCF-mediated ERK phosphorylation was completely inhibited by AG1296. These data demonstrate that the constitutive STAT5 phosphorylation that could be inhibited by AG1296 is exclusively mediated by Flt3.
Spontaneous apoptosis of AML blasts correlated with constitutive STAT5 phosphorylation
Next we examined whether the constitutive STAT5 phosphorylation has biological significance for AML blasts, eg an effect on the viability of the cells. Therefore, we examined whether the degree of constitutive STAT5 phosphorylation coincided with the amount of spontaneous apoptosis. AML cells were cultured for 24 h in 10% FBS and the percentage of apoptotic cells was determined by annexinV/PI staining. As shown in Table 1 , in the AML cases that demonstrated a high degree of constitutive STAT5 phosphorylation a relatively low percentage of apoptotic cells was observed (median 24%; range 9-30%) (Nos 1-3, 5-11). This in contrast to the AML cases with no or very low levels of phospho-STAT5. Ten of the 11 AMLs with low phospho-STAT5 demonstrated a relatively high number of apoptotic cells (median 59%; range 40-95%) (Nos 12, 13, (15) (16) (17) 19, 20, (22) (23) (24) (25) . Four AML cases that demonstrated constitutive STAT5 phosphorylation dem-
Figure 2
Flt3 receptor is constitutively phosphorylated in majority of STAT5 positive AML cases. (a) 2 × 10 7 AML cells were cultured for 24 h in RPMI 1640 supplemented with 10% FBS. Cell lysates were prepared and Flt3 was immunoprecipitated from the lysates. After SDS-PAGE, Western blotting was performed using antibodies against phosphotyrosine (PY) or Flt3. (b) AML cells were cultured overnight in RPMI 1640 medium supplemented with 10% FBS and subsequently stimulated for 5 min with medium or FL (100 ng/ml). Cell lysates were prepared and Flt3 was immunoprecipitated from the lysates. After SDS-PAGE, Western blotting was performed using antibodies against phosphotyrosine (PY) or Flt3. (c) AML cells (case 23) were cultured overnight in RPMI 1640 supplemented with 10% FBS. Subsequently cells were stimulated for 10 min with the indicated AML supernatants or FL as a positive control. Total cell extracts were prepared and subjected to SDS-PAGE. Western blotting was performed using antibodies against phospho-STAT5 and STAT5 A/B. (d) AML cells were cultured overnight in RPMI 1640 medium with 10% FBS with or without anti-GM-CSF (1 g/ml) . Total cell extracts were prepared and subjected to SDS-PAGE. Western blotting was performed using antibodies against phospho-STAT5 and STAT5 A/B.
Figure 3
Specific tyrosine kinase III inhibitor AG1296 inhibits FLinduced STAT5 and ERK phosphorylation. (a) AML cells were cultured overnight in RPMI 1640 supplemented with 10% FBS. Subsequently cells were pre-incubated for 90 min with AG1296 (20 M) and then stimulated for 10 min with FL (100 ng/ml). Total cell extracts were prepared and subjected to SDS-PAGE. Western blotting was performed using antibodies against phospho-STAT5, STAT5 A/B, phospho-ERK1/2 and ERK1/2. (b) AML cells were cultured overnight in RPMI 1640 supplemented with 10% FBS. Subsequently cells were pre-incubated for 90 min with AG1296 (20 M) or AG490 (100 M) and then stimulated for 10 min with FL (100 ng/ml) or GM-CSF (10 ng/ml). Total cell extracts were prepared and subjected to SDS-PAGE. Western blotting was performed using antibodies against phospho-STAT5 and STAT5 A/B. (c) AML cells were cultured overnight in RPMI 1640 supplemented with 10% FBS. Subsequently cells were pre-incubated for 90 min with AG1296 (20 M) and then stimulated for 5 min with FL (100 ng/ml). Cell lysates were prepared and Flt3 was immunoprecipitated from the lysates. After SDS-PAGE, Western blotting was performed using antibodies against phosphotyrosine (PY) or Flt3. 
The receptor tyrosine kinaseIII inhibitor AG1296 enhances apoptosis of AML blasts
In order to investigate whether the Flt3-mediated STAT5 phosphorylation indeed prevented AML blasts from apoptosis, the effect of AG1296 on the spontaneous apoptosis of three AML cases with high constitutive Flt3 and STAT5 phosphorylation was investigated (AML Nos 1, 3, 6 ). The number of apoptotic cells of all three AML cases was increased with 16 ± 2% in the presence of AG1296.
Next, we examined whether the inhibition of STAT5 and Flt3 phosphorylation by AG1296 and the subsequent increase in the number of apoptotic cells was reflected at the level of Bcl-xl expression since it has been described that STAT5 exerts its survival-promoting effect by enhancing expression of the anti-apoptotic Bcl-xl protein. The Bcl-xl gene contains STAT5 binding sites and induction of a constitutive active STAT5 mutant was shown to enhance Bcl-xl levels. 41, 42 Therefore, the effect of AG1296 on Bcl-xl protein expression of AML cases with high STAT5 and Flt3 phosphorylation was examined after 24 h of incubation. As demonstrated in Figure  5 , the AML cases studied all demonstrated high basal Bcl-xl protein expression levels. Addition of AG1296 had no distinct effect on Bcl-xl protein expression of these AML cases. AG1296 has no distinct effect on Bcl-xl protein expression. AML cells were cultured overnight in RPMI 1640 supplemented with 10% FBS with or without AG1296 (20 M). Total cell extracts were prepared and equal amounts of cell lysates were subjected to SDS-PAGE. Western blot analysis was performed using an antibody against Bcl-xl.
Discussion
Constitutive activation of signal transducer and activator of transcription (STAT) proteins 1, 3 and 5 has been described to occur in patients with acute myeloid leukemia (AML). 17, 18 Although several reports demonstrated spontaneous phosphorylation of STAT5 in AML, the exact underlying mechanism of this constitutive activation has not yet been unraveled. It has been described that constitutive STAT3 activation in AML is caused by high IL-6 secretion levels, stimulating the JAK/STAT3 pathway in an autocrine manner. 19 However, here we provide evidence that constitutive STAT5 tyrosine phosphorylation is caused by different mechanisms. In the majority of the cases (71%) constitutive STAT5 phosphorylation was associated with autophosphorylation of the Flt3 receptor, which coincided with tandem duplications of the Flt3 gene in 47% (eight of 17) of the cases, while 24% (four of 17) of the cases demonstrated STAT5 phosphorylation and Flt3 autophosphorylation without mutations. A subset of the AML cases (29%) had no autophosphorylation of the Flt3 receptor, but demonstrated constitutive STAT5 phosphorylation, which was in part due to autocrine growth factor production.
It appears that the receptor tyrosine kinase Flt3 plays a role in the constitutive STAT5 tyrosine phosphorylation of AML blasts. Here, we demonstrate that 71% of the investigated AML cases with constitutive STAT5 phosphorylation also demonstrated constitutive Flt3 phosphorylation. The largest group with constitutive STAT5 phosphorylation demonstrated constitutive Flt3 phosphorylation, which coincided with tandem duplications in the Flt3 receptor (47%). Somatic mutations of Flt3, in which the juxtamembrane domain has an internal tandem duplication (ITD), have been found in 20% of AML cases. 30 These mutations result in constitutive tyrosine phosphorylation of the receptor. 32 However, it appears that in the case of a heterozygous mutation, the mutation does not result in maximal activation of the receptor, since stimulation with FL further enhanced Flt3 phosphorylation. This is most probably due to the contribution of the wild-type Flt3 receptor chain, which can still be phosphorylated following FL stimulation. The second group of AML cases demonstrated constitutive STAT5 and Flt3 phosphorylation although no Flt3 mutations were detectable (24%). This constitutive Flt3 phosphorylation is most likely not due to autocrine production of Flt3 ligand, since stimulation with conditioned medium of these AML cases did not result in the activation of STAT5. Therefore, the constitutive Flt3 phosphorylation might either be due to Leukemia mutations in some yet unknown kinase, responsible for the Flt3 phosphorylation, or due to an activating point mutation of Flt3. Recently, it has been described that replacement of Asp-838 by valine results in an activating mutation of the Flt3 receptor, rendering 32Dcl3 myeloid progenitor cells factor independent. 43 In these cells Flt3 was constitutively autophosphorylated. In addition, Yamamoto et al 44 demonstrated in 7% of AML cases activating point mutations in amino acid D835 of Flt3, leading to constitutive tyrosine phosphorylation of the receptor.
Our data strongly suggest a correlation between the constitutive Flt3 phosphorylation and STAT5 phosphorylation. We clearly demonstrate that Flt3 activation results in STAT5 phosphorylation of AML blasts. Addition of the receptor tyrosineIII kinase inhibitor AG1296, which has been described earlier as a potent inhibitor for Flt3, 29 strongly inhibited the spontaneous Flt3 and STAT5 phosphorylation. In addition, stimulation with Flt3 ligand strongly enhanced STAT5 tyrosine phosphorylation and ERK phosphorylation, which was inhibited by AG1296. However, the constitutive Flt3 phosphorylation of the AML cases with a homozygous or heterozygous mutation could not be inhibited by AG1296, while STAT5 phosphorylation was strongly inhibited. This might be due to the fact that the mutation leads to a conformational change of the receptor, which results in constitutive phosphorylation, and which cannot be affected by the inhibitor. Therefore, AG1296 might interfere by inhibiting binding of STAT5 to the receptor. The possibility that AG1296 might inhibit another kinase responsible for STAT5 phosphorylation such as c-kit, a receptor tyrosine kinase which has been described to be also inhibited by AG1296, 39 has been excluded due to the fact that c-kit ligand (stem cell factor) was not able to induce STAT5 phosphorylation.
Flt3 mutations, however, are not in all cases associated with Flt3 autophosphorylation. In a subgroup of patients (13%) this finding was observed. Similar data have been described by Fenski et al, 43 who demonstrated that internal tandem duplications do not always cause constitutive activation of Flt3. It is likely that the variability in length of the tandem duplications of the different AML cases might be determinative for the dimerization and the subsequent activation of the receptor and the downstream signaling pathways. Future studies will elucidate whether the different tandem duplications are of significance for the different phosphorylation events.
Finally, in 29% of the cases STAT5 phosphorylation was not linked to Flt3 phosphorylation. In two of three investigated cases the autocrine secretion of GM-CSF is partly responsible for STAT5 phosphorylation, indicating that in a subset of cases the spontaneous secretion of growth factors is responsible for STAT5 phosphorylation, as has been observed for STAT3. 19 Considering the biological significance of constitutive active Flt3, we provide evidence that the constitutive activation of Flt3 has a function in the prevention of apoptosis of AML blasts. Our data suggest that constitutive active Flt3 prevents apoptosis of AML blasts by activating downstream signaling pathways which might include STAT5. The AML cases with high constitutive Flt3 and STAT5 phosphorylation demonstrated a much lower percentage of apoptotic cells. In addition, AG1296 increased the percentage of spontaneous apoptosis of these AML cases.
Previously, it was reported that the Bcl-xl gene contains STAT5 binding sites and induction of a constitutive active STAT5 mutant was found to enhance Bcl-xl protein levels. 41, 42 However, here we demonstrate that inhibition of STAT5 phosphorylation by AG1296 did not affect Bcl-xl expression levels.
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Similar results have been obtained by Sillaber et al 20 They demonstrated that a dominant negative STAT5 mutant did not affect Bcl-xl expression in Bcr-Abl transformed cells. Since more signaling pathways than just the STAT5 pathway are involved in the expression of Bcl-xl, eg NF-B, 45 it might be that inhibition of only one of these pathways is not enough to reduce the expression of Bcl-xl. In addition, a recent report indicated that a second signaling pathway is involved, such as PI3-K, to actually modulate Bcl-xl expression. 46 In summary, these data demonstrate that constitutive STAT5 phosphorylation is caused by different mechanisms, but in the majority of the cases STAT5 phosphorylation is caused by Flt3 phosphorylation, mostly due to mutations in the receptor, and is associated with a low degree of spontaneous apoptosis.
